<DOC>
	<DOCNO>NCT02053454</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics ( PK ) patisiran ( ALN-TTR02 ) Japanese subject</brief_summary>
	<brief_title>A Study Safety , Tolerability Pharmacokinetics ALN-TTR02 Japanese Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Healthy Japanese adult male female age 20 65 year , inclusive ( The subject born Japan live outside Japan &lt; 10 year , subject 's biological parent grandparent fully Japanese born Japan ) ; Subjects healthy determine clinical assessment ; Females subject must nonchildbearing potential ; Males partner childbearing potential , must agree use appropriate contraception . Subjects history serious mental illness ; Subjects clinically relevant medical surgical history ; Subjects positive screen alcohol drug abuse ; Subjects safety laboratory test result deem clinically significant ; Subjects know hepatitis B surface antigen ( HBsAg ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) infection ; Subjects receive investigational agent within 3 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>RNAi therapeutic</keyword>
</DOC>